Prescribing information


Prescribing information


Resources for HCPs to share with patients who have been prescribed ILARIS® (canakinumab) to treat their periodic fever syndrome.

This video explains the correct injection technique for patients and caregivers administering ILARIS.

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only. If you do wish to share this video with patients, please share this link:


Preview of the ILARIS patient information leaflet


This guide helps patients understand what to expect from treatment with ILARIS for their periodic fever syndrome.


Preview of the ILARIS guide for adult patients on Period Fever Syndromes

A guide for adult patients on Periodic Fever Syndromes, what causes them and how ILARIS can help.



Preview of the ILARIS guide for paediatric patients to help them learn all about Period Fever Syndromes

A guide for paediatric patients to help them learn all about Periodic Fever Syndromes and how ILARIS can help them.





ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HCP, healthcare professional; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Rate this content: 
Average: 5 (1 vote)
UK | November 2021 | 160463

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]